Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies.
Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies.
复制标题
抑郁症中的纤溶酶原激活剂抑制剂 1：动物和临床研究的结果。
DOI：
10.1038/srep30464
复制
发表时间：
2016-07-26
影响因子：
4.6
通讯作者：
Yuan Y
中科院分区：
文献类型：
--
作者：
Jiang H;Li X;Chen S;Lu N;Yue Y;Liang J;Zhang Z;Yuan Y
有证据表明，纤溶酶原激活物抑制剂-1（派-1）是一种应激相关因子，并且在抑郁症（MDD）患者中血清派-1水平升高。在此，我们分析了派-1蛋白水平在脑，脑脊液（CSF）和血清的啮齿动物暴露于慢性不可预测的轻度压力或治疗艾司西酞普兰。此外，我们还检测了17名无药物抑郁症患者在艾司西酞普兰治疗前后的血清派-1浓度。我们发现，派-1的表达增加，在1区的扣带皮层和前边缘皮层的内侧前额叶皮层，以及在海马角amnus 3和齿状回在应激大鼠。派-1在慢性艾司西酞普兰治疗后下调，在应激大鼠的CSF和血清中派-1水平高于对照组，尽管在血清中差异没有达到统计学意义。艾司西酞普兰治疗显著降低了血清中的派-1水平，但未降低CSF中的PAI-1水平。MDD患者血清派-1浓度显著高于对照组。我们的研究结果表明，派-1是牵连在抑郁症的病理生理。
Evidence suggests that plasminogen activator inhibitor-1 (PAI-1) is a stress-related factor, and serum PAI-1 levels are increased in patients with major depressive disorders (MDD). Herein, we analysed PAI-1 protein levels in the brain, cerebrospinal fluid (CSF) and serum of rodents exposed to chronic unpredictable mild stress or treated with escitalopram. In addition, we examined PAI-1 concentrations in serum obtained from 17 drug-free depressed patients before and after escitalopram treatment. We found that PAI-1 expression was increased in area 1 of the cingulate cortex and prelimbic cortex of the medial prefrontal cortex as well as in the hippocampal cornu ammonis 3 and dentate gyrus in stressed rats. A downregulation of PAI-1 following chronic escitalopram treatment was also found. PAI-1 levels were higher in the CSF and serum in stressed rats than in controls, although the difference did not reach statistical significance in the serum. Escitalopram treatment significantly decreased PAI-1 levels in the serum, but not in the CSF. MDD patients had significantly greater serum PAI-1 concentrations than controls. Our results suggest that PAI-1 is implicated in the pathophysiology of depression.